|
May 10
|
C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic Collaborations
|
|
May 8
|
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
Apr 29
|
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 9
|
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
|
|
Apr 8
|
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
|
|
Mar 28
|
Here’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)
|
|
Mar 5
|
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
|
|
Mar 4
|
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
|
|
Jan 11
|
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
|
|
Jan 9
|
C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden Cross
|
|
Jan 9
|
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
|
|
Jan 5
|
Axsome (AXSM) Surges 7.8%: Is This an Indication of Further Gains?
|
|
Jan 4
|
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
|
|
Jan 4
|
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Jan 1
|
Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High?
|
|
Dec 29
|
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
|
|
Dec 28
|
The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics
|
|
Dec 28
|
11 Hot Healthcare Stocks To Buy Now
|
|
Nov 28
|
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
|
|
Aug 8
|
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates
|